Project no.: HIV-NAT 118/MATRIX
This is a prospective, open-label, single arm study that assesses the efficacy and safety of fixed dose combination of TDF/3TC/EFV.
Results: The generic FDC of TDF/3TC/EFV was well tolerated and efficacious. Our findings lend support to the use of this generic FDC as first-line antiretroviral therapy in resource limited settings.
Presentation: Maekanantawat W, Avihingsanon A, Thainsanguankul W, Wongsabut J, Gorowara M, Ramautarsing R, Clarke A, Hsu D, Ruxrungtham K. Safety and efficacy of once daily single generic fixed drug combination tablet of Tenofovir, Lamivudine and Efavirenz among HIV infected Thais. [Poster # P312] was presented at the International Congress on Drug Therapy in HIV. Glasgow, Glasgow, UK. November 11-15, 2012
Publications: Submitted
